FDA Brief

Warning letters Food

FDA warning letter to

New Sun Inc.

High riskIssued Jun 8, 2022Posted Jul 19, 2022Office of Human and Animal Foods- East Division 3

New Sun Inc. marketed dietary supplements and CBD products as unapproved drugs with disease-treatment claims, including CBD products for children.

What happened

FDA inspected New Sun's Hendersonville, NC facility on October 28-29, 2021, collecting product labels and brochures, and reviewed the company website in May 2022. FDA found the products were promoted with claims to cure, treat, or prevent diseases, making them unapproved new drugs; FDA also said CBD products cannot be dietary supplements and highlighted marketing of Advanced CBD Oil as safe for children.

What FDA found

  1. The products are drugs because website and labeling claims say they cure, treat, or prevent diseases.

    section 201(g)(1) of the Act [21 U.S.C. 321(g)(1)]
  2. The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and have no FDA-approved application.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The CBD products are marketed as dietary supplements, but FDA says CBD is excluded from the dietary supplement definition.

    section 201(ff)(3)(B)(i) and (ii) of the Act [21 U.S.C. 321(ff)(3)(B)(i) and (ii)]
  4. The products are misbranded because they lack adequate directions for use for diseases that require a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]
  5. The company markets Advanced CBD Oil (Hemp Oil) as safe for children even though FDA has not evaluated it for safety, effectiveness, and quality.

What FDA wants

FDA asks New Sun to notify it in writing within 15 working days of the steps taken to correct the violations, including an explanation of each step and copies of related documentation. If corrections cannot be completed in that time, the company must state the reason for delay and when it will finish.

Who should pay attention

  • dietary supplement brands that make disease claims
  • CBD product marketers
  • retailers selling supplements or CBD products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk